Janoray G, Barillot I, Calais G
Clinique d'oncologie radiothérapie, centre Henry-S.-Kaplan, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
Clinique d'oncologie radiothérapie, centre Henry-S.-Kaplan, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
Cancer Radiother. 2014 Jul-Aug;18(4):320-4. doi: 10.1016/j.canrad.2014.02.007. Epub 2014 May 5.
Stereotactic body radiation therapy takes more and more an important place in the therapeutic arsenal of primitive and secondary liver tumours. The administration of ablative radiation doses can result in specific changes to both the tumour and the healthy hepatic parenchyma, relative to conventional radiation therapy, making the assessment of local changes after stereotactic body radiation therapy, in terms of local control and reaction of healthy tissue, often difficult. It is mandatory to standardize and simplify our evaluation criteria to benefit from a better understanding of the effectiveness of this new treatment modality and allow better reproducibility of available imaging exams. This article presents a literature review of the various radiological changes observed after stereotactic body radiation therapy for liver tumours according to the multiple assessment methods used to determine local control. From the data available, we recommend using modified RECIST criteria proposed by the American Association for the Study of Liver Diseases (AASLD), as objective and relevant criteria of local control after stereotactic body radiation therapy for liver tumours.
立体定向体部放射治疗在原发性和继发性肝肿瘤的治疗手段中占据着越来越重要的地位。与传统放射治疗相比,给予消融性放射剂量会导致肿瘤和健康肝实质都发生特定变化,这使得在局部控制和健康组织反应方面评估立体定向体部放射治疗后的局部变化往往很困难。必须规范和简化我们的评估标准,以便更好地理解这种新治疗方式的有效性,并使现有影像检查具有更好的可重复性。本文根据用于确定局部控制的多种评估方法,对肝肿瘤立体定向体部放射治疗后观察到的各种放射学变化进行了文献综述。根据现有数据,我们建议使用美国肝病研究协会(AASLD)提出的改良RECIST标准,作为肝肿瘤立体定向体部放射治疗后局部控制的客观且相关的标准。